脾多肽联合GP方案治疗晚期肺鳞状细胞癌的临床疗效  

Efficacy of Lienal Polypeptide Injection Combined with GP Regimen in the Treatment of Advanced Squamous Cell Carcinoma of the Lung

作　　者：于德东[1] 郝志强[1] 朱巍[1] 白雪莲[1] 刘波[1] 武云[1] YU De-dong;HAO Zhi-qiang;ZHU Wei;BAI Xue-lian;LIU Bo;WU Yun(Baotou Central Hospital,Baotou,Inner Mongolia,China)

机构地区：[1]内蒙古包头市中心医院

出　　处：《世界最新医学信息文摘》2018年第21期15-16,共2页World Latest Medicine Information Electronic Version

摘　　要：目的晚期肺癌的治疗以化疗为主,但是化疗副反应常影响治疗顺利进行。本研究评价采用脾多肽注射液辅助吉西他滨+顺铂联合化疗方案(GP)治疗晚期肺鳞状细胞癌观察其疗效和不良反应。方法采用随机数字法将60例晚期肺鳞状细胞癌患者随机分为两组:a组(30例)采用脾多肽注射液联合吉西他滨+顺铂治疗;B组(30例)单用吉西他滨+顺铂治疗。a组于开始使用GP方案时即行脾多肽注射液10ml/d(含25mg多肽)静脉点滴,连续应用10d。分别于治疗前后对患者外周血白细胞、血小板、血红蛋白水平、肝肾功能、食欲、消化道反应、体重、Ps评分、疗效进行评价。结果 a组及B组的疾病控制率分别为71.4%和41.4%,两组间差异有显著性(P=0.022)。a组及B组Pfs分别为6.3个月和5.1个月(P=0.000)。a组的生活质量显著改善,与B组比较差异有显著性(P<0.05)。a组白细胞、中性粒细胞及血小板水平减少程度均较B组轻。结论脾多肽注射液联合GP方案治疗晚期肺鳞状细胞癌可以增加疗效,减轻骨髓毒性及消化道反应,提高患者生活质量和化疗耐受性,值得临床推广应用。Objective The chemotherapy is main measures on advanced lung cancer, but side effects of chemotherapy frequently influenced treatment go smoothly. This study evaluated the efficacy and side effects of Lienal Polypeptide Injection plus gemcitabine plus cisplatin combined chemotherapy（GP） in the treatment of advanced lung squamous cell carcinoma. Methods Sixty patients were randomly divided into two groups： group A： Lienal Polypeptide Injection plus gemcitabine ＋ cisplatin; group B： only administered gemcitabine ＋ cisplatin. In the A group, the intravenous drip of the Lienal Polypeptide Injection 10 mL/d（containing 25 mg polypeptide）was performed when the GP scheme began to use, and 10 d was used continuously. Before and after treatment, we evaluated the white blood cell, platelet, hemoglobin level, liver and kidney function, appetite, gastrointestinal reaction, body weight, PS score and curative effect before and after treatment. Results The rate of disease control in group A and group B was 71.4% and 41.4% respectively, and there was a significant difference between the two groups（P=0.022）. The PFS of group A and group B were 6.3 months and 5.1 months respectively（P=0.000）. The quality of life of group A was significantly improved, and there was a significant difference compared with group B（P0.05）. The levels of leukocyte, neutrophils and platelets in group A were less than that in group B. Conclusion Lienal Polypeptide Injection combined with GP regimen can improve the curative effect, reduce bone marrow toxicity and gastrointestinal reactions, improve the quality of life and chemotherapy tolerance of patients with advanced lung squamous cell carcinoma, and is worthy of clinical application.

关 键 词：肺鳞状细胞癌 化疗 脾多肽注射液 

分 类 号：R734.2[医药卫生—肿瘤]